synthetic peptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-09-02. Numbers and descriptions here follow the published literature rather than marketing material.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic cyclic heptapeptide | Analog of alpha-MSH with an internal lactam bridge |
| Molecular weight | Approximately 1024 daltons | Free base value; salt forms differ |
| Appearance | White to off-white powder | Usually supplied as a lyophilized solid |
| Solubility | Freely soluble in water | Poorly soluble in nonpolar solvents |
| Typical storage | −20 °C, dry, protected from light | Repeated freeze-thaw cycles degrade peptides |
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Early published reports described melanotan-2 as a tanning agent without sun protection, which means darkening is not the same as protection against ultraviolet radiation. Later studies explored the peptide in erectile dysfunction, hemorrhagic shock, and some skin conditions. No regulator in the United States or Europe has approved it for clinical use. Many products labelled melanotan-2 are sold without approval and their identity and purity are unverified. Its long-term safety in humans remains an open question.
Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
== Use and effects == Isoergine occurs naturally in morning glory species, including Ipomoea tricolor (tlitliltzin), Ipomoea corymbosa (ololiuhqui), and Argyreia nervosa (Hawaiian baby woodrose). It has been found to constitute 8 to 35% of total alkaloid content relative to 5 to 58% for ergine. Albert Hofmann, the discoverer of LSD's psychedelic effects, tried 2 mg isoergine orally and experienced feelings of unreality, detachment from the outside world, feelings of mental emptiness, tiredness, and apathy, though no specific sensory distortions were mentioned. He described its effects as similar to those of ergine, which he had tested at doses of up to 2 mg. Subsequently Heim and colleagues assessed ergine at higher doses of 3 to 6 mg orally and observed toxic-like effects, while isoergine at 2 to 5 mg orally produced notable hallucinogenic effects. The psychedelic effects of isoergine observed in this study included some euphoria, synaesthesia, and altered time perception. However, although hallucinogenic, isoergine's effects have been described as not LSD-like. The presence of hallucinogenic effects of isoergine has been described as quite unusual for an isolysergamide derivative. It is thought that ergine and isoergine together may account for most or all of the effects of morning glory seeds, with ergine producing intoxication, sedation, and autonomic side effects and isoergine producing hallucinogenic effects. Conversely, other notable constituents, including elymoclavine, lysergol, and chanoclavine, produced no psychoactive or hallucinogenic effects in humans.
== Since November 2022 == On April 20, 2023, Twitter (known as X since July 2023) began removing verification status for users of public interest, causing a controversy among Twitter users. The website's system was altered, allowing any individual to receive verification for a monthly fee, an act which saw significant criticism. Following the acquisition of Twitter by Elon Musk on October 28, 2022, Musk told Twitter employees to introduce paid verification by November 7 through Twitter Blue. The Verge reported that the updated Blue subscription would cost $19.99 per month, and users would lose their verification status if they did not join within 90 days. Following backlash, Musk tweeted, in response to author Stephen King, a lowered $8 price on November 1, 2022. Twitter confirmed the new price of $7.99 per month on November 5, 2022. The new verification system began rollout on November 9, 2022, a day after the 2022 United States elections. The decision to delay its rollout was to address concerns about users potentially spreading misinformation about voting results by posing as news outlets and lawmakers. At the same time, Twitter introduced a secondary gray "Official" label on some high-profile accounts, but removed them hours after launch. Less than 48 hours later, Twitter reinstated the gray "Official" label, after multiple users were suspended for deliberately impersonating reporters and high-profile athletes like LeBron James.
Since the beginning of the 21st century, fast food has been criticized for its animal welfare record, its links to obesity and its environmental impact. Eric Schlosser's book Fast Food Nation (2002) and Morgan Spurlock's film Super Size Me (2004) reflected these concerns. Since 2003, People for the Ethical Treatment of Animals (PETA) has protested KFC's choice of poultry suppliers worldwide. The exception is KFC Canada, which signed an agreement pledging to only use "animal-friendly" suppliers. President of KFC's US division Gregg Dedrick said PETA mischaracterized KFC as a poultry producer rather than a purchaser of chickens. In 2008, Yum! stated: "[As] a major purchaser of food products, [Yum!] has the opportunity and responsibility to influence the way animals supplied to us are treated. We take that responsibility very seriously, and we are monitoring our suppliers on an ongoing basis." In 2006, Greenpeace accused KFC Europe of sourcing the soya bean for its chicken feed from Cargill, which had been accused of clearing large swathes of the Amazon rainforest in order to grow the crop. In 2010, according to The Guardian, "in the US where fried chicken remains closely associated with age-old racist stereotypes about black people in the once segregated south", KFC Australia aired the 30-second promotion on television named "KFC's cricket survival guide" which shows a white cricket fan surrounded by black fans from the opposing team.
In pharmacology, an inverse agonist is a drug that binds to the same receptor as an agonist but induces a pharmacological response opposite to that of the agonist. A neutral antagonist has no activity in the absence of an agonist or inverse agonist but can block the activity of either; they are in fact sometimes called blockers (examples include alpha blockers, beta blockers, and calcium channel blockers). Inverse agonists have opposite actions to those of agonists but the effects of both of these can be blocked by antagonists. A prerequisite for an inverse agonist response is that the receptor must have a constitutive (also known as intrinsic or basal) level of activity in the absence of any ligand. An agonist increases the activity of a receptor above its basal level, whereas an inverse agonist decreases the activity below the basal level. The efficacy of a full agonist is by definition 100%, a neutral antagonist has 0% efficacy, and an inverse agonist has < 0% (i.e., negative) efficacy.
Sources: en.wikipedia.org
== Functions == Anabolic processes build organs and tissues. These processes produce growth and differentiation of cells and increase in body size, a process that involves synthesis of complex molecules. Examples of anabolic processes include the growth and mineralization of bone and increases in muscle mass.
== Special relativity == With the discovery of special relativity by Henri Poincaré and Albert Einstein, the energy was proposed to be a component of an energy-momentum 4-vector. Each of the four components (one of energy and three of momentum) of this vector is separately conserved across time, in any closed system, as seen from any given inertial reference frame. Also conserved is the vector length (Minkowski norm), which is the rest mass for single particles, and the invariant mass for systems of particles (where momenta and energy are separately summed before the length is calculated). The relativistic energy of a single massive particle contains a term related to its rest mass in addition to its kinetic energy of motion. In the limit of zero kinetic energy (or equivalently in the rest frame) of a massive particle, or else in the center of momentum frame for objects or systems which retain kinetic energy, the total energy of a particle or object (including internal kinetic energy in systems) is proportional to the rest mass or invariant mass, as described by the equation
This species is of typical elongated tetra appearance; it is of plain basic coloration, but with two distinct, adjacent, longitudinal stripes, white above black. The eye has two thin but distinctive color bands across the top, red above yellow. It grows to a maximum overall length of approximately 4 cm (1.6 in). Befitting its common name, it slightly resembles the neon tetra, which belongs to a different genus (Paracheirodon). Females are often larger than males. The variety named Diamond or Brilliant does not have a white stripe but instead displays more reflective scales around the head. The fish's natural diet consists of small invertebrates and plants. H. herbertaxelrodi is commonly kept as an aquarium fish by hobbyists. The black neon tetra is sometimes called the black tetra, but that name more properly refers to a different species, Gymnocorymbus ternetzi.
== Prevalence == Since there is no regular autoantibody screening, patients with LADA are at risk of being diagnosed with type 2 diabetes, which makes it difficult to estimate the prevalence of LADA. Globally, it is estimated that about 8.5% of adults have some form of diabetes and it is estimated that LADA accounts for about 3-12% of all adult diabetes cases. 2015 estimates suggest that up to 10–20% of people with diabetes have LADA.
=== Other copper-related hereditary syndromes === Other diseases in which abnormalities in copper metabolism appear to be involved include Indian childhood cirrhosis (ICC), endemic Tyrolean copper toxicosis (ETIC), and idiopathic copper toxicosis (ICT), also known as non-Indian childhood cirrhosis. ICT is a genetic disease recognized in the early twentieth century primarily in the Tyrolean region of Austria and in the Pune region of India. ICC, ICT, and ETIC are infancy syndromes that are similar in their apparent etiology and presentation. Both appear to have a genetic component and a contribution from elevated copper intake. In cases of ICC, the elevated copper intake is due to heating and/or storing milk in copper or brass vessels. ICT cases, on the other hand, are due to elevated copper concentrations in water supplies. Although exposures to elevated concentrations of copper are commonly found in both diseases, some cases appear to develop in children who are exclusively breastfed or who receive only low levels of copper in water supplies. The currently prevailing hypothesis is that ICT is due to a genetic lesion resulting in impaired copper metabolism combined with high copper intake. This hypothesis was supported by the frequency of occurrence of parental consanguinity in most of these cases, which is absent in areas with elevated copper in drinking water and in which these syndromes do not occur.
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide modeled on alpha-melanocyte-stimulating hormone. It carries two non-natural substitutions and a cyclic bridge that increase its stability relative to the natural hormone. It circulates as a research chemical and is not an approved medicine.
Melanotan-1, also called afamelanotide, is a shorter linear analog with a different amino acid sequence and no lactam ring. It has been evaluated in formal clinical programs, while melanotan-2 has not. The two are distinct molecules and are not interchangeable.
No. Bremelanotide is a related but distinct cyclic peptide that reached approved status for one specific clinical indication. Melanotan-2 is a separate molecule with its own sequence and properties. Shared ancestry in the melanocortin family does not make them the same substance.
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.